 |
| T-Cell Lymphoma Market |
T-cell lymphoma is one of the major types of non-Hodgkin's lymphoma
characterized by abnormal growth of certain white blood cells called T
lymphocytes. Targeted therapies used for treatment of T-cell lymphoma offers
advantages such as minimal side effects and increased efficacy. Drugs for
T-cell lymphoma target specific molecules on lymphoma cells and interfere with
their growth with minimal damage to normal cells. The global T-cell Lymphoma
Market is estimated to be valued at US$
1961.64 Mn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Market key trends:
The adoption of targeted therapies is expected to accelerate the growth of the
T-cell lymphoma market during the forecast period. Targeted therapies such as
monoclonal antibodies provide opportunities to investigate new ways to treat
T-cell lymphoma by interfering specifically with lymphoma cell growth signals
without harming normal cells. Drugs such as Brentuximab vedotin, Adcetris and
Polatuzumab vedotin target specific molecules on lymphoma cells involved in
their growth and survival. These targeted drugs have shown promising results with
minimal side effects in clinical trials. With increasing awareness and benefits
of targeted therapies, the T-cell lymphoma market is expected to witness
significant growth over the forecast period.
Segment Analysis
The global T-cell Lymphoma market is dominated by peripheral T-cell lymphoma
segment. This is because peripheral T-cell lymphoma is more common and
aggressive as compared to other subtypes. It accounts for nearly 15% of all
cases of non-Hodgkin lymphoma (NHL) in the US and 10-15% of cases in Europe.
Its incidence increases with age and among people with weakened immune systems.
Key Takeaways:
The global T-Cell
Lymphoma Market Growth is expected to witness high growth during the
forecast period of 2023-2030. The market size for 2023 is estimated to be US$
1961.64 Mn. The global T-cell Lymphoma Market is estimated to be valued at US$
1961.64 Mn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast
period 2023 to 2030
Regional analysis:
North America region currently dominates the global T-cell Lymphoma market due
to high incidences of lymphoma as well as presence of established players. The
region is estimated to hold around 45% of the total market share in 2023 owing
to increasing healthcare spending and growing adoption of advanced treatment
therapies.
Key players:
Key players operating in the T-cell Lymphoma market are B. Braun Melsungen AG,
Fagron NV, PharMEDium Services, LLC (AmerisourceBergen Corporation), Baxter
International Inc., Fresenius Kabi AG, Advanced Pharma, Inc., McGuff
Compounding Pharmacy Services, Inc., Central Admixture Pharmacy Services, Inc.
(CAPS), Institutional Pharmacy Solutions, LLC, Wedgewood Pharmacy, Medisca
Inc., Dougherty's Holdings, Inc., PharMEDium Services, LLC (AmerisourceBergen
Corporation), PharMEDium Services, LLC, (AmerisourceBergen Corporation),
BioScrip, Inc. These players are focusing on new product launches and
expansions to strengthen their market presence.
0 Comments